Diabetic macular edema: New concepts in patho-physiology and treatment

Cell and Bioscience

Volumn 4, Issue 1, 2014, Pages

  Zhang, Xinyuan ^a,b   Zeng, Huan ^a   Bao, Shian ^c   Wang, Ningli ^a   Gillies, Mark C ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Apoptosis; Diabetic retinopathy; Microvasculopathy; Neuronal degenerative diseases; Therapeutic strategy

Indexed keywords

EID: 84902078367     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/2045-3701-4-27     Document Type: Review

References (115)

1. Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Yamamoto H. Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J Pharmacol Sci 2005, 97:305-311. 10.1254/jphs.CPJ04005X, 15750291.
2. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008, 57:1026-1033. 10.2337/db07-0982, 2836241, 18174522.
3. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic Macular Edema: Pathogenesis and Treatment. Surv Ophthalmol 2009, 54:1-32. 10.1016/j.survophthal.2008.10.001, 19171208.
4. Bailey CC, Sparrow JM, Grey RH, Cheng H. The National Diabetic Retinopathy Laser Treatment Audit. III. Clinical outcomes. Eye (Lond) 1999, 13(Pt 2):151-159.
5. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O'Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, Wang N, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012, 35:556-564. 10.2337/dc11-1909, 3322721, 22301125.
6. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 1989, 96:1501-1510. 10.1016/S0161-6420(89)32699-6, 2587045.
7. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. Jama 2007, 298:902-916. 10.1001/jama.298.8.902, 17712074.
8. White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, Davis MD, . for the D-ERG Effect of Prior Intensive Therapy in Type 1 Diabetes on 10-Year Progression of Retinopathy in the DCCT/EDIC: Comparison of Adults and Adolescents. Diabetes 2010, 59:1244-1253. 10.2337/db09-1216, 2857905, 20150283, for the D-ERG.
9. Wang N, Xu X, Zou H, Zhu J, Wang W, Ho PC. The status of diabetic retinopathy and diabetic macular edema in patients with type 2 diabetes: a survey from Beixinjing District of Shanghai city in China. Ophthalmologica 2008, 222:32-36. 10.1159/000109276, 18097178.
10. Xie XW, Xu L, Wang YX, Jonas JB. Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefes Arch Clin Exp Ophthalmol 2008, 246:1519-1526. 10.1007/s00417-008-0884-6, 18604548.
11. Wang FH, Liang YB, Zhang F, Wang JJ, Wei WB, Tao QS, Sun LP, Friedman DS, Wang NL, Wong TY. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmol 2009, 116:461-467.
12. Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 2004, 53:2883-2892. 10.2337/diabetes.53.11.2883, 15504969.
13. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009, 116:497-503. 10.1016/j.ophtha.2008.10.016, 2693093, 19167079.
14. Ashton N, Cunha-Vaz JG. EFFECT OF HISTAMINE ON THE PERMEABILITY OF THE OCULAR VESSELS. Arch Ophthalmol 1965, 73:211-223. 10.1001/archopht.1965.00970030213014, 14237791.
15. Shakib M, Cunha-Vaz JG. Studies on the permeability of the blood-retinal barrier. IV. Junctional complexes of the retinal vessels and their role in the permeability of the blood-retinal barrier. Exp Eye Res 1966, 5:229-234. 10.1016/S0014-4835(66)80011-8, 5914655.
16. Cunha-Vaz JG. The blood-retinal barriers system. Basic concepts and clinical evaluation. Exp Eye Res 2004, 78:715-721. 10.1016/S0014-4835(03)00213-6, 15106951.
17. González-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol 2003, 81:1-44. 10.1016/S0079-6107(02)00037-8, 12475568.
18. Cunha-Vaz JG. The blood-retinal barriers. Doc Ophthalmol 1976, 41:287-327. 10.1007/BF00146764, 1009819.
19. Matter K, Balda MS. Signalling to and from tight junctions. Nat Rev Mol Cell Biol 2003, 4:225-236. 10.1038/nrm1055, 12612641.
20. Felinski EA, Antonetti DA. Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res 2005, 30:949-957. 10.1080/02713680500263598, 16282129.
21. Gillies MC, Su T, Stayt J, Simpson JM, Naidoo D, Salonikas C. Effect of high glucose on permeability of retinal capillary endothelium in vitro. Invest Ophthalmol Vis Sci 1997, 38:635-642.
22. Feldman GJ, Mullin JM, Ryan MP. Occludin: structure, function and regulation. Adv Drug Deliv Rev 2005, 57:883-917. 10.1016/j.addr.2005.01.009, 15820558.
23. Furuse M, Tsukita S. Claudins in occluding junctions of humans and flies. Trends Cell Biol 2006, 16:181-188. 10.1016/j.tcb.2006.02.006, 16537104.
24. Saitou M, Furuse MS H, Schulzke JD, Fromm M, Takano H, Noda T, Tsukita S. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol Biol Cell 2000, 11:4131-4142. 10.1091/mbc.11.12.4131, 15062, 11102513.
25. Pan L, Chen J, Yu J, Yu H, Zhang M. The structure of the PDZ3-SH3-GuK tandem of ZO-1 protein suggests a supramodular organization of the membrane-associated guanylate kinase (MAGUK) family scaffold protein core. J Biol Chem 2011, 286:40069-40074. 10.1074/jbc.C111.293084, 3220542, 21965684.
26. Keil JM, Liu X, Antonetti DA. Glucocorticoid induction of occludin expression and endothelial barrier requires transcription factor p54 NONO. Invest Ophthalmol Vis Sci 2013, 54:4007-4015. 10.1167/iovs.13-11980, 3681474, 23640037.
27. Mary Gregory DGC. Identification of multiple claudins in the rat epididymis. Mol Reprod Dev 2006, 73:580-588. 10.1002/mrd.20467, 16489631.
28. Hou J, Gomes AS, Paul DL, Goodenough DA. Study of claudin function by RNA interference. J Biol Chem 2006, 281:36117-36123. 10.1074/jbc.M608853200, 17018523.
29. Morris AP, Tawil A, Berkova Z, Wible L, Smith CW, Cunningham SA. Junctional Adhesion Molecules (JAMs) are differentially expressed in fibroblasts and co-localize with ZO-1 to adherens-like junctions. Cell Commun Adhes 2006, 13:233-247. 10.1080/15419060600877978, 16916751.
30. Ebnet K, Suzuki A, Ohno S, Vestweber D. Junctional adhesion molecules (JAMs): more molecules with dual functions?. J Cell Sci 2004, 117:19-29. 10.1242/jcs.00930, 14657270.
31. Weber C, Fraemohs L, Dejana E. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol 2007, 7:467-477. 10.1038/nri2096, 17525755.
32. Deissler HL, Deissler H, Lang GK, Lang GE. VEGF but not PlGF disturbs the barrier of retinal endothelial cells. Exp Eye Res 2013, 115:162-171.
33. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999, 274:23463-23467. 10.1074/jbc.274.33.23463, 10438525.
34. Muthusamy A, Lin C-M, Shanmugam S, Lindner HM, Abcouwer SF, Antonetti DA. Ischemia-reperfusion injury induces occludin phosphorylation/ubiquitination and retinal vascular permeability in a VEGFR-2-dependent manner. J Cereb Blood Flow Metab 2014, 34:522-531. 10.1038/jcbfm.2013.230, 24398936.
35. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985. 10.1126/science.6823562, 6823562.
36. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989, 161:851-858. 10.1016/0006-291X(89)92678-8, 2735925.
37. Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990, 50:1774-1778.
38. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25. 10.1210/edrv.18.1.0287, 9034784.
39. Breen EC. VEGF in biological control. J Cell Biochem 2007, 102:1358-1367. 10.1002/jcb.21579, 17979153.
40. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002, 62:4123-4131.
41. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 2005, 48:2422-2427. 10.1007/s00125-005-1951-8, 16193288.
42. Cebe Suarez AZ, FaKB H. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 2006, 63:601-615. 10.1007/s00018-005-5426-3, 2773843, 16465447.
43. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001, 276:3222-3230. 10.1074/jbc.M002016200, 11058584.
44. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000, 19:5598-5605. 10.1038/sj.onc.1203855, 11114740.
45. Herzog Y, Kalcheim C, Kahane N, Reshef R, Neufeld G. Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech Dev 2001, 109:115-119. 10.1016/S0925-4773(01)00518-4, 11677062.
46. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676. 10.1038/nm0603-669, 12778165.
47. Zhang X, Bao S, Hambly BD, Gillies MC. Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. Int J Biochem Cell Biol 2009, 41:2368-2371. 10.1016/j.biocel.2009.07.011, 19646547.
48. Leal EC, Manivannan A, Hosoya K, Terasaki T, Cunha-Vaz J, Ambrosio AF, Forrester JV. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 2007, 48:5257-5265. 10.1167/iovs.07-0112, 17962481.
49. Mohammad G, Siddiquei MM, Othman A, Al-Shabrawey M, Abu El-Asrar AM. High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Exp Eye Res 2013, 107:101-109.
50. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmol 2009, 116:73-79.
51. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K, Yoshimura N. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005, 46:1440-1444. 10.1167/iovs.04-0905, 15790913.
52. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996, 2:992-997. 10.1038/nm0996-992, 8782456.
53. Joussen AM, Poulaki V, Qin W, Kirchhof B, Mitsiades N, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 2002, 160:501-509. 10.1016/S0002-9440(10)64869-9, 1850650, 11839570.
54. Vinores SA, Xiao WH, Shen J, Campochiaro PA. TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J Neuroimmunol 2007, 182:73-79. 10.1016/j.jneuroim.2006.09.015, 1800833, 17107717.
55. Matsuoka M, Ogata N, Minamino K, Matsumura M. Leukostasis and pigment epithelium-derived factor in rat models of diabetic retinopathy. Mol Vis 2007, 13:1058-1065. 2776541, 17653050.
56. Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, Amano S, Hida T, Oguchi Y, Adamis AP. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003, 44:2155-2162. 10.1167/iovs.02-0807, 12714656.
57. Del Maschio A, Zanetti A, Corada M, Rival Y, Ruco L, Lampugnani MG, Dejana E. Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions. J Cell Biol 1996, 135:497-510. 10.1083/jcb.135.2.497, 2121047, 8896605.
58. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008, 30:65-84. 10.1007/s00281-008-0111-x, 18340447.
59. Joussen APV, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, Adamis AP. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. Faseb J 2002, 16:438-440.
60. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012, 366:1227-1239. 10.1056/NEJMra1005073, 22455417.
61. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007, 55:498-510. 10.1016/j.phrs.2007.04.016, 17574431.
62. Sotiropoulos K. Protein Kinase C (PKC) Activation in Circulating Mononuclear Cells - Potential Surrogate Marker for Diabetic Retinopathy and Other Microangiopathic Diseases. Invest Ophthalmol Vis Sci 2002, 43:557.
63. Kunisaki M, Bursell SE, Umeda F, Nawata H, King GL. Prevention of diabetes-induced abnormal retinal blood flow by treatment with d-alpha-tocopherol. Biofactors 1998, 7:55-67. 10.1002/biof.5520070109, 9523029.
64. Titchenell PM, Lin CM, Keil JM, Sundstrom JM, Smith CD, Antonetti DA. Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction. Biochem J 2012, 446:455-467. 10.1042/BJ20111961, 3767384, 22721706.
65. Amadio M, Scapagnini G, Lupo G, Drago F, Govoni S, Pascale A. PKCbetaII/HuR/VEGF: A new molecular cascade in retinal pericytes for the regulation of VEGF gene expression. Pharmacol Res 2008, 57:60-66. 10.1016/j.phrs.2007.11.006, 18206386.
66. Suzuma K, Takahara N, Suzuma I, Isshiki K, Ueki K, Leitges M, Aiello LP, King GL. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci USA 2002, 99:721-726. 10.1073/pnas.022644499, 117372, 11805327.
67. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790. 10.1038/35008121, 10783895.
68. Harhaj NS, Felinski EA, Wolpert EB, Sundstrom JM, Gardner TW, Antonetti DA. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci 2006, 47:5106-5115. 10.1167/iovs.06-0322, 17065532.
69. Nonaka A, Kiryu J, Tsujikawa A, Yamashiro K, Miyamoto K, Nishiwaki H, Honda Y, Ogura Y. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 2000, 41:2702-2706.
70. Kim YH, Kim YS, Park CH, Chung IY, Yoo JM, Kim JG, Lee BJ, Kang SS, Cho GJ, Choi WS. Protein kinase C-delta mediates neuronal apoptosis in the retinas of diabetic rats via the Akt signaling pathway. Diabetes 2008, 57:2181-2190. 10.2337/db07-1431, 2494683, 18443201.
71. Soetikno V, Sari FR, Sukumaran V, Lakshmanan AP, Mito S, Harima M, Thandavarayan RA, Suzuki K, Nagata M, Takagi R, Watanabe K. Curcumin prevents diabetic cardiomyopathy in streptozotocin-induced diabetic rats: possible involvement of PKC-MAPK signaling pathway. Eur J Pharm Sci 2012, 47:604-614. 10.1016/j.ejps.2012.04.018, 22564708.
72. Peppa M, Uribarri J, Vlassara H. Glucose, Advanced Glycation End Products, and Diabetes Complications: What Is New and What Works. Clin Diabetes 2003, 21:186-187.
73. Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, Yamamoto Y, Yamamoto H, Adamis AP. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 2007, 48:858-865. 10.1167/iovs.06-0495, 17251488.
74. Sun C, Liang C, Ren Y, Zhen Y, He Z, Wang H, Tan H, Pan X, Wu Z. Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic Res Cardiol 2009, 104:42-49. 10.1007/s00395-008-0738-8, 18622638.
75. Knels L, Worm M, Wendel M, Roehlecke C, Kniep E, Funk RH. Effects of advanced glycation end products-inductor glyoxal and hydrogen peroxide as oxidative stress factors on rat retinal organ cultures and neuroprotection by UK-14,304. J Neurochem 2008, 106:1876-1887.
76. Wang AL, Yu AC, He QH, Zhu X, Tso MO. AGEs mediated expression and secretion of TNF alpha in rat retinal microglia. Exp Eye Res 2007, 84:905-913. 10.1016/j.exer.2007.01.011, 17359975.
77. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita Z. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002, 16:1928-1930.
78. Kobayashi T, Oku H, Komori A, Okuno T, Kojima S, Obayashi H, Sugiyama T, Hasegawa G, Fukui M, Nakamura N, Ikeda T. Advanced glycation end products induce death of retinal neurons via activation of nitric oxide synthase. Exp Eye Res 2005, 81:647-654. 10.1016/j.exer.2005.04.001, 15975578.
79. Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 2004, 53:2404-2411. 10.2337/diabetes.53.9.2404, 15331552.
80. Akagi Y, Kador PF, Kuwabara T, Kinoshita JH. Aldose reductase localization in human retinal mural cells. Invest Ophthalmol Vis Sci 1983, 24:1516-1519.
81. Ronald GT. Diabetic vascular dysfunction: Links to glucose-induced reductive stress and VEGF. Microsc Res Tech 2002, 57:390-407. 10.1002/jemt.10092, 12112445.
82. Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A, Lorenzi M. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 2003, 52:506-511. 10.2337/diabetes.52.2.506, 12540628.
83. Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 2006, 55:2757-2762. 10.2337/db06-0138, 17003340.
84. Drel VR, Pacher P, Ali TK, Shin J, Julius U, El-Remessy AB, Obrosova IG. Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. Int J Mol Med 2008, 21:667-676. 2527815, 18506358.
85. Horal M, Zhang Z, Stanton R, Virkamaki A, Loeken MR. Activation of the hexosamine pathway causes oxidative stress and abnormal embryo gene expression: involvement in diabetic teratogenesis. Birth Defects Res A Clin Mol Teratol 2004, 70:519-527. 10.1002/bdra.20056, 15329829.
86. Weigert C, Brodbeck K, Sawadogo M, Haring HU, Schleicher ED. Upstream stimulatory factor (USF) proteins induce human TGF-beta1 gene activation via the glucose-response element-1013/-1002 in mesangial cells: up-regulation of USF activity by the hexosamine biosynthetic pathway. J Biol Chem 2004, 279:15908-15915. 10.1074/jbc.M313524200, 14757763.
87. Goldberg HJ, Whiteside CI, Fantus IG. The hexosamine pathway regulates the plasminogen activator inhibitor-1 gene promoter and Sp1 transcriptional activation through protein kinase C-beta I and -delta. J Biol Chem 2002, 277:33833-33841. 10.1074/jbc.M112331200, 12105191.
88. Nakamura M, Barber AJ, Antonetti DA, LaNoue KF, Robinson KA, Buse MG, Gardner TW. Excessive hexosamines block the neuroprotective effect of insulin and induce apoptosis in retinal neurons. J Biol Chem 2001, 276:43748-43755. 10.1074/jbc.M108594200, 11560942.
89. Xue M, Qian Q, Adaikalakoteswari A, Rabbani N, Babaei-Jadidi R, Thornalley PJ. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 2008, 57:2809-2817. 10.2337/db06-1003, 2551693, 18633117.
90. Hammes H, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003, 9:294-299. 10.1038/nm834, 12592403.
91. Cameron NE, Cotter MA. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest 1995, 96:1159-1163. 10.1172/JCI118104, 185307, 7635953.
92. Tuck RR, Schmelzer JD, Low PA. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 1984, 107(Pt 3):935-950.
93. Ouchi M, West K, Crabb JW, Kinoshita S, Kamei M. Proteomic analysis of vitreous from diabetic macular edema. Exp Eye Res 2005, 81:176-182. 10.1016/j.exer.2005.01.020, 16080911.
94. Nasrallah FP, Jalkh AE, Van Coppenolle F, Kado M, Trempe CL, McMeel JW, Schepens CL. The role of the vitreous in diabetic macular edema. Ophthalmol 1988, 95:1335-1339.
95. Abrishami M, Moosavi MN, Shoeibi N, Hosseinpoor SS. Intravitreal tissue plasminogen activator to treat refractory diabetic macular edema by induction of posterior vitreous detachment. Retina 2011, 31:2065-2070. 10.1097/IAE.0b013e31820f49ff, 21983248.
96. Nowosielska A, Robaszkiewicz J, Graczynska E, Czarnecki W, Stankiewicz A. [The influence of spontaneous posterior vitreous detachment in resolution of diabetic macular edema in NIDDM]. Klin Oczna 2003, 105:355-361.
97. Maeda M, Yamamoto I, Fukuda M, Motomura T, Nishida M, Nonen S, Fujio Y, Kasayama S, Azuma J. MTHFR gene polymorphism is susceptible to diabetic retinopathy but not to diabetic nephropathy in Japanese type 2 diabetic patients. J Diabetes Complications 2008, 22:119-125. 10.1016/j.jdiacomp.2006.12.002, 18280442.
98. Chen Y, Huang H, Zhou J, Doumatey A, Lashley K, Chen G, Agyenim-Boateng K, Eghan BA, Acheampong J, Fasanmade O, Johnson T, Akinsola FB, Okafor G, Oli J, Ezepue F, Amoah A, Akafo S, Adeyemo A, Rotimi CN. Polymorphism of the endothelial nitric oxide synthase gene is associated with diabetic retinopathy in a cohort of West Africans. Mol Vis 2007, 13:2142-2147.
99. Cheung AK, Fung MK, Lo AC, Lam TT, So KF, Chung SS, Chung SK. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes 2005, 54:3119-3125. 10.2337/diabetes.54.11.3119, 16249434.
100. Buraczynska M, Baranowicz-Gaszczyk I, Borowicz E, Ksiazek A. TGF-beta1 and TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes. Nephron Physiol 2007, 106:p69-p75. 10.1159/000104874, 17622752.
101. Wu L, Fernandez-Loaiza P, Sauma J, Hernandez-Bogantes E, Masis M. Classification of diabetic retinopathy and diabetic macular edema. World J Diabetes 2013, 4:290-294. 10.4239/wjd.v4.i6.290, 3874488, 24379919.
102. Marmor MF. Mechanisms of fluid accumulation in retinal edema. Doc Ophthalmol 1999, 97:239-249. 10.1023/A:1002192829817, 10896337.
103. Bandello F, Pognuz R, Polito A, Pirracchio A, Menchini F, Ambesi M. Diabetic macular edema: classification, medical and laser therapy. Semin Ophthalmol 2003, 18:251-258. 10.1080/08820530390895262, 15513012.
104. ETDRS Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985, 103:1796-1806. ETDRS.
105. ETDRS Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmol 1991, 98:766-785. ETDRS.
106. Diabetic Retinopathy Clinical Research Network A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmol 2008, 115:1447-1449. 1449 e1441-1410, Diabetic Retinopathy Clinical Research Network.
107. The Diabetic Retinopathy Study Research Group Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmol 1981, 88:583-600. The Diabetic Retinopathy Study Research Group.
108. Gardner TW. Complications of retinal laser therapy and their prevention. Semin Ophthalmol 1991, 6:19-26. 10.3109/08820539109060177, 10149515.
109. Dorin G. Evolution of retinal laser therapy: minimum intensity photocoagulation (MIP). Can the laser heal the retina without harming it?. Semin Ophthalmol 2004, 19:62-68. 10.1080/08820530490884173, 15590536.
110. Lavinsky D, Cardillo JA, Melo LA, Dare A, Farah ME, Belfort R. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci 2011, 52:4314-4323. 10.1167/iovs.10-6828, 21345996.
111. Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev 2012, 8:274-284. 10.2174/157339912800840523, 3412206, 22587512.
112. Ohkoshi K, Yamaguchi T. Subthreshold micropulse diode laser photocoagulation for diabetic macular edema in Japanese patients. Am J Ophthalmol 2010, 149:133-139. 10.1016/j.ajo.2009.08.010, 19875091.
113. Machemer R, Buettner H, Norton EW, Parel JM. Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol 1971, 75:813-820.
114. Machemer R, Parel JM, Buettner H. A new concept for viteous surgery. I. Instrumentation. Am J Ophthalmol 1972, 73:1-7.
115. Davids MD, Blodi BA. Retina. Proliferative Diabetic Retinopathy 2001, 1309-1349. Ryan SJ, Schachat AP, Third, Retina. Volume Two.